Clinical trial · Observational
The Function of PET Molecular Imaging Targeting Fibroblast Activation Protein in the Hepatobiliary Malignancies
The Role of Novel PET Molecular Imaging Targeting Fibroblast Activation Protein in the Diagnosis of Hepatobiliary Malignancies
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Patients with high clinical suspicion of hepatobiliary malignancies should undergo PET/CT examination with two imaging agents, 68Ga-FAPI (fibroblast activation protein inhibitor) and 18F-FDG within one week, and collect tumor tissue. Finally, the PET/CT results were compared with the pathology report to evaluate the role of 68Ga-FAPI PET/CT imaging in the diagnosis of hepatobiliary malignancies
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatobiliary Diseases | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 68Ga-FAPI-04 imaging agent | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- diagnose accordance rate
- timeFrame
- 2022.1.20-2022.7.30
- description
- Proportion of PET/CT diagnostic reports consistent with pathological results
Secondary outcomes (5)
- measure
- Standardized Uptake Mean (SUVmean)
- timeFrame
- 2022.1.20-2022.7.30
- description
- The average of the standard uptake value
- measure
- Standardized Uptake Maximum (SUVmax)
- timeFrame
- 2022.1.20-2022.7.30
- description
- The maximum value of the standard uptake value
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: 1. Voluntarily participate and sign a written informed consent; 2. 18-80 years old (inclusive) male or female; 3. Patients with high clinical suspicion of hepatobiliary malignancy in combination with medical history and imaging studies, etc. 4. Those who obtained pathological diagnosis results through needle biopsy or surgical resection; 5. Have willingness and ability to participate in all research procedures. Exclusion Criteria: 1. Women who are pregnant or breastfeeding; 2. Those who are known to be allergic to the imaging agent 68Ga-FAPI or its excipients; 3. Those who have a history of other malignant tumors in the past; 4. Before the injection of 18F-FDG, the fasting blood glucose level exceeds 11.0mmol/L; 5. Patients with claustrophobia; 6. Those who cannot tolerate lying down for 15-30 minutes; 7. The researchers believe that it is not suitable to participate in this clinical trial; 8. Those who have participated in clinical trials or are participating in other clinical trials within the past month
References
Publications (0)
Data not yet available